article in the WSJ about Biogen buying Reata Pharm
Post# of 145570
![](/assets/46931549/no_avatar_available_thumb.jpg)
so, that's 7X revenue from 2028 - and their indications are for rare disease, so not very big markets at all. just shows you - if we can just get our #$%& together, our valuation should soar.
TO DO ITEMS:
1. hire impressive, business-minded CEO
2. get hold lifted
3. ink partnerships
4. sell for +$10
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)